{"organizations": [], "uuid": "b80b2481137e1bc2db1eee388140b97db952803b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-axsome-therapeutics-says-its-cns-d/brief-axsome-therapeutics-says-its-cns-disorder-candidate-axs-09-met-main-goal-of-phase-1-trial-idUSASB0C7D9", "country": "US", "domain_rank": 408, "title": "BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T14:13:00.000+02:00", "replies_count": 0, "uuid": "b80b2481137e1bc2db1eee388140b97db952803b"}, "author": "", "url": "https://www.reuters.com/article/brief-axsome-therapeutics-says-its-cns-d/brief-axsome-therapeutics-says-its-cns-disorder-candidate-axs-09-met-main-goal-of-phase-1-trial-idUSASB0C7D9", "ord_in_thread": 0, "title": "BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "trial reuters staff", "sentiment": "none"}, {"name": "axsome therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 26, 2018 / 12:13 PM / Updated 9 minutes ago BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial Reuters Staff 1 Min Read Feb 26 (Reuters) - Axsome Therapeutics Inc: * AXSOME THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 1 TRIAL OF NEXT GENERATION PRODUCT CANDIDATE AXS-09 CONTAINING CHIRALLY PURE ESBUPROPION AND DEXTROMETHORPHAN * AXSOME THERAPEUTICS INC - ‍CHIRALLY PURE AND STABLE SINGLE ENANTIOMERS OF BUPROPION ACHIEVED​ * AXSOME THERAPEUTICS INC - ‍AXS-09 WAS WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED IN TRIAL​ * AXSOME THERAPEUTICS INC - ‍ AXS-09 RESULTS IN SUBSTANTIAL INCREASES IN DEXTROMETHORPHAN PLASMA LEVELS​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-26T14:13:00.000+02:00", "crawled": "2018-02-26T14:26:06.001+02:00", "highlightTitle": ""}